Allianz SE Purchases 1,260 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Allianz SE grew its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 25,181 shares of the pharmaceutical company’s stock after purchasing an additional 1,260 shares during the period. Allianz SE’s holdings in Vertex Pharmaceuticals were worth $11,416,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Swiss RE Ltd. purchased a new stake in Vertex Pharmaceuticals during the fourth quarter valued at about $28,000. Eagle Bay Advisors LLC bought a new position in shares of Vertex Pharmaceuticals during the fourth quarter valued at approximately $29,000. IMG Wealth Management Inc. increased its stake in shares of Vertex Pharmaceuticals by 277.8% during the fourth quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock valued at $31,000 after purchasing an additional 50 shares in the last quarter. Colonial Trust Co SC increased its stake in shares of Vertex Pharmaceuticals by 118.8% during the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 38 shares in the last quarter. Finally, Ares Financial Consulting LLC bought a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at approximately $33,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX opened at $444.92 on Friday. The company’s fifty day moving average price is $437.14 and its 200-day moving average price is $452.33. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $507.92. The firm has a market capitalization of $112.92 billion, a P/E ratio of 26.39, a PEG ratio of 1.90 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.24 by $0.23. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The firm had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $2.99 billion. During the same period last year, the business earned $4.06 earnings per share. Vertex Pharmaceuticals’s revenue was up 8.3% compared to the same quarter last year. Equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 17.02 EPS for the current fiscal year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Joy Liu sold 1,104 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $425.02, for a total transaction of $469,222.08. Following the sale, the executive vice president directly owned 20,729 shares in the company, valued at approximately $8,810,239.58. The trade was a 5.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sangeeta N. Bhatia sold 318 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $423.73, for a total transaction of $134,746.14. Following the completion of the sale, the director directly owned 4,924 shares in the company, valued at approximately $2,086,446.52. The trade was a 6.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 11,133 shares of company stock valued at $4,973,106. 0.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Truist Financial assumed coverage on shares of Vertex Pharmaceuticals in a report on Wednesday, May 27th. They issued a “buy” rating and a $542.00 target price on the stock. Bank of America raised their target price on shares of Vertex Pharmaceuticals from $571.00 to $598.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Barclays raised their target price on shares of Vertex Pharmaceuticals from $607.00 to $615.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Morgan Stanley raised their target price on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the stock an “overweight” rating in a report on Tuesday, May 5th. Finally, Wall Street Zen cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 30th. Twenty-two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $555.91.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex received bullish attention from market commentary highlighting that Wall Street remains interested in the stock despite a bearish “death cross” technical setup, suggesting investors are focusing more on the company’s fundamentals than the chart pattern. Article Title
• Positive Sentiment: The company announced new CASGEVY data at the European Hematology Association Congress, including the first European presentation of results in children ages 5–11 and additional global regulatory submissions, which could support longer-term growth for the gene-editing therapy. Article Title
• Positive Sentiment: Analysts and media coverage have been broadly upbeat on Vertex, including pieces describing it as a favored healthcare stock and a stock some investors view as attractive to buy now, reinforcing confidence in the name. Article Title
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate for Vertex to $19.24 from $19.36, a small revision that may not materially change the long-term outlook but is a minor headwind for sentiment. Article Title
• Negative Sentiment: The stock has also experienced a recent pullback in some sessions, reflecting normal volatility and some profit-taking even as the broader narrative remains constructive. Article Title

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.